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Abstract. The immunosuppressant cyclosporine A (CsA)
is a specific pharmacological inhibitor of calcineurin, the
Ca2+-calmodulin activated phospho-Ser/Thr-specific protein
phosphatase. Although calcineurin-inhibiting compounds are
applied for local treatment of psoriasis or atopic dermatitis
in dermatological practice, little is known about the functions
of calcineurin in epidermis-derived malignancies. We inves-
tigated the effects of CsA on two human melanoma cell lines,
the metastasis forming HT168 and WM35 established from
an RGP primary lesion. CsA of 2 μM lowered the enzyme
activity by 50% and caused elevation in both mRNA and
protein expression of calcineurin. Cell proliferation was
diminished, as well as the cellular morphology and the actin
organization were altered in both cell lines. CsA increased
cell death moderately in both cell lines and reduced the
metabolic activity of HT168 cells, but not that of WM35 cells.
CsA also elevated the expressions of both Bcl-2 and ERK1/2.
Fibronectin guided migration of HT168 cells was stimulated
under the effect of CsA, while that of WM35 cells was
reduced, moreover, HT168 cells switched from the
expression of ß3 to ß1 integrin, but WM35 cells continued to
express ß3. Based on our results we propose a multiple, partly
malignancy-dependent role of calcineurin in these
melanoma cell lines.
Introduction
Calcineurin or PP2B is a Ca-calmodulin activated phospho-
Ser/Thr-specific protein phosphatase, which was first detected
in brain and skeletal muscle (1), and is best known as a key
regulator of T-lymphocyte activation via dephosphorylation
and consequent nuclear translocation of the transcription
factor: Nuclear Factor of Activated T-lymphocytes (NFAT)
(2,3).
Pharmacological inhibitors of calcineurin, such as cyclo-
sporine A (CsA), tacrolimus or pimecrolimus recently became
popular in the dermatological practice for topic treatment
of diseases of skin which accompany activation of T-lympho-
cytes, e.g. atopic dermatitis (4). Local application of these
compounds have no significant side effects (5), but it is
reported that long-term systemic application of calcineurin
inhibitors as immunosuppressants following organ trans-
plantations may increase the incidence of skin tumours,
particularly squamous cell carcinoma (6).
Some physiological roles of calcineurin played in keratino-
cytes have been reported recently. It serves as a factor in the
regulation of the terminal differentiation of keratinocytes (7)
and it modulates the DNA repair following UV irradiation
(8). Application of calcineurin inhibitors for the treatment of
hypopigmentary skin disorders has also been suggested (9),
but the investigation of the physiological role of calcineurin
in the biology of melanocytes, the pigment producing cells
of epidermis, has just started (10).
Melanocytes develop from neural crest during embryonic
life and have intense ability of migration in this period.
Differentiated melanocytes regularly do not proliferate or
migrate in adult epidermis and are under tight control of
keratinocytes (11). Cutaneous malignant melanoma origi-
nating from the melanocytes of the epidermis, is a highly
malignant variant of skin tumours with a very poor prognosis
if it starts to form metastases, since melanoma cells are
highly resistant to any kind of conventional chemotherapy
or irradiation. The results of experiments carried out during
the last two decades revealed that malignant transformation
of melanocytes is associated with overexpression and/or over-
activation of various Ser/Thr-specific protein kinases, e.g.
protein kinase C (12), protein kinase A (13) or MAP kinases
(14). The importance of these signal transduction molecules
in the ethiopathogenesis of melanoma is underlined by the
fact that pharmacological inhibitors of these enzymes are
promising therapeutic drugs of this malignancy (15-17).
Although the presumed role of Ser/Thr-protein phosphatases
in the altered signal transduction pathways is beyond question,
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little is known about the function of these enzymes in the
cellular mechanisms of melanoma cells. As changes of the
intracellular Ca-concentration are reported to be involved in
the different cellular functions of melanoma cells such as
migration (18) or cellular viability (19), it seems likely that
calcineurin may play a role in the regulation of these
processes.
The aim of our study was to investigate the possible
role(s) of calcineurin in the major cellular functions of two
human melanoma cell lines; one of which (HT168) represents
an experimental model of a highly metastatic melanoma (20),
while the other (WM35) was isolated from a radial growth
phase (RGP) primary lesion (21), and might be a good model
of a less malignant, non-metastatic type of this malignancy.
We report herein that inhibition of calcineurin by CsA caused
different alterations in the morphology, actin organization,
proliferation, viability, as well as fibronectin guided migration
of the two melanoma cell lines. Furthermore, we found that
CsA increased both the expression and the phosphorylation
of ERK1/2, and it also elevated the protein level of Bcl-2
and modulated the ß3 and ß1 integrin expression pattern of
melanoma cells. Based on our findings we suggest a multiple
role of calcineurin in melanoma cells which partly depends
on the stage of malignancy.
Materials and methods
Cultures of melanoma cell lines. Human melanoma cell line
HT168 was selected from A2058 cell line according to its
metastasis formation in immunosuppressed mice (20), while
WM35 was established from a primary cutaneous melanoma
of radial growth phase (21). Both cell lines were provided
by Dr J. Tímár (National Institute of Oncology, Budapest,
Hungary). Cells were cultured in RPMI culture medium
(Sigma, Budapest, Hungary) supplemented with 5% foetal
bovine serum (HyClone, South Logan, UT), 2 mM L-glu-
tamine (Gibco, Gaithersburg, MD), penicillin (100 units/ml)
and streptomycin (100 μg/ml) at 37˚C in the presence of 95%
air and 5% CO2 atmosphere and 80% humidity in 25 cm2
flasks (Orange Scientifique, Braine-l'Alleud, Belgium) until
approximately 70% confluence. Activity of calcineurin was
inhibited by continuous application of 2 μM CsA (Sigma)
starting 2 days before confluence.
Light microscopical morphology analysis. Melanoma cells
of different experimental groups were cultured on the surface
of rectangular coverglasses (Menzel-Gläser, Menzel GmbH,
Braunschweig, Germany) placed into Petri dishes. After
rinsing, cells were fixed in a 4:1 mixture of absolute ethanol
and 40% formaldehyde, stained with haematoxylin and eosin
(Sigma) and mounted in gum arabic. Photomicrographs of
cells were taken using a Spot Advanced camera on a Nikon
Eclipse E800 microscope (Nikon Corporation, Tokyo, Japan).
Immunocytochemistry. For immunocytochemistry cells
were cultured on the surface of rectangular coverglasses as
described above. For calcineurin immunocytochemistry cells
were fixed in Sainte-Marie solution (22) and washed in 70%
ethanol. After rinsing in PBS, cells were blocked with PBS
supplemented with 1% bovine serum albumin, then incubated
in a polyclonal Pan-calcineurin A antibody (Cell Signaling
Technology, Danvers, MA) at a dilution of 1:400 at 4˚C over-
night. For visualisation of the primary antibody, FITC-
conjugated anti-rabbit secondary antibody (Vector Labo-
ratories, Peterborough, UK) was used at a dilution of 1:1000.
Cultures were mounted in Vectashield Hard Set mounting
medium (Vector Laboratories) containing DAPI to visualise
the nuclei. To demonstrate actin, cells were fixed in acetone
at -20˚C for 20 min. After washing at room temperature with
calcium magnesium-free phosphate buffer solution (CMF-
PBS), TRITC-Phalloidin (Sigma) was applied at a dilution
of 1:300 (23). Cultures were viewed by fluorescence micro-
scopy (Nikon Eclipse E800, Nikon Corporation). All images
were acquired using constant camera settings to allow
comparison of staining intensities.
Migration assay. Cells were washed twice in CMF-PBS,
harvested with 0.25% trypsin (Sigma) and resuspended in
RPMI in a density of 2x105 cells/ml. Lower wells of Boyden
chamber (Neuro Probe Inc., Gaithersburg, MD) were filled
with 1 μl/ml human fibronectin (Sigma) dissolved in CMF-
PBS and covered with a polycarbonate filter (Neuro Probe
Inc.) containing pores with a diameter of 3 μm. Cell sus-
pension (50 μl) was inoculated into the wells on the top
of the membrane and the chamber was incubated for 3 h
at 37˚C in a humidified atmosphere (5% CO2-95% air).
Non-migrated cells were removed from the surface of the
membrane and after fixation in methanol, migrated cells
were stained with 1% toluidine blue (Sigma) dissolved in
water (24). Membranes were air-dried and mounted with
gum arabic. Absolute cell numbers were counted using a
light microscope.
Measurement of apoptosis using flow cytometry. After
48 h of treatment with CsA, the amount of apoptotic cells
was determined using an Annexin V DY647 kit (Central
European Biosystems, Budapest, Hungary) (25) and the ratio
of necrotic cells was measured after staining with propidium
iodide (PI, Sigma). Untreated cells were used as control.
After washing twice in CMF-PBS, cells were incubated
in 10 μl Annexin V DY647 and/or PI at room temperature
for 10 min. Before harvesting with 0.25% trypsin, cells were
washed with Annexin V binding buffer or CMF-PBS. Cell
pellets were resuspended in 1000 μl FACS buffer (PBS
supplemented with 1% BSA and 0.05% NaN3) and were
analysed with a CyFlow® space Flow Cytometer (Partec
GmbH, Münster, Germany). Annexin V DY647 was moni-
tored at 670 nm and PI was detected at 430 nm. Measurement
lower threshold was set on cell-size particles. Analysis was
performed using WinMDI 2.8 freeware (Joseph Trotter,
http://facs.scripps.edu/). Quadrants of Annexin/PI density
plots were set as follows: Annexin-/PI-; Annexin+/PI-;
Annexin-/PI+; Annexin+/PI+ populations.
Measurement of cell proliferation with 3H-thymidine
labelling and mitochondrial activity with MTT-assay.
Medium containing 1 μCi/ml 3H-thymidine (185 GBq/mM
3H-thymidine, Amersham Biosciences, Budapest, Hungary)
was added to cells cultured in wells of 24-well plates for
16 h on 2nd day of CsA treatment. After washing with PBS,
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proteins were precipitated with ice-cold 5% trichloroacetic
acid for 20 min. After washing with PBS again, cells were
harvested using 0.25% trypsin for 30 min and collected with
centrifugation at 2000 x g. The pellet was resuspended in
10 μl CMF-PBS and placed into wells of special opaque
96-well plates (Wallac, PerkinElmer Life and Analytical
Sciences, Shelton, CT). The plates were placed in an exsic-
cator containing phosphorous pentoxide in order to absorb
moisture. Prior to measurements, 50 μl scintillation solution
(MaxiLight; Hidex Ltd., Turku, Finland) was added to
each well and radioactivity was counted by a liquid scinti-
llation counter (Chameleon Microplate Reader, Hidex Ltd.,
Turku, Finland). For investigation of mitochondrial activity,
cells were cultured in wells of 24-well plates and MTT-
assays were performed measuring the absorption at 570 nm
(Chameleon Microplate Reader).
Determination of cytosolic free Ca2+ concentration.
Measurements were performed on melanoma cell cultures
with approximately 70% confluence using the calcium-
dependent fluorescent dye Fura-2 (TEFLabs, Inc. Austin,
TX). Cell lines were transferred to 2 ml fresh RPMI medium
containing 10 ml Fura-2-AM (10 μM) and 4 μl neostigmin
(0.3 nM) to inhibit extracellular choline esterases. After
60 min of incubation at 37˚C in a CO2 incubator, cultures
were washed twice in Tyrode's solution (137 mM NaCl,
5.4 mM KCl, 0.5 mM MgCl2, 1.8 mM CaCl2, 11.8 mM
Hepes, 1 g/l glucose, pH 7.4). Fura-2-loaded cells were placed
on the stage of an inverted fluorescent microscope and viewed
using a x40 oil immersion objective. Measurements were
carried out in the above described Tyode's solution in a
perfusion chamber using a dual wavelength monochromator
(DeltaScan, Photon Technologies International, Lawren-
ceville, KY) equipment. Fluorescence was measured using
excitation wavelengths of 340 and 380 nm and an emission
wavelength of 510 nm. Cytosolic free Ca2+ concentrations
were calculated from the ratios of intensities (R = F340/F380)
as described (26).
Western blot analysis. Total cell lysates were examined by
Western blot. Samples for SDS-PAGE were prepared by the
addition of 100 μl of 5-fold concentrated electrophoresis
sample buffer (20 mM Tris-HCl pH 7.4, 0.01% bromophenol
blue dissolved in 10% SDS, 100 mM ß-mercaptoethanol) to
cell lysates and boiled for 10 min. About 60 μg of protein
was separated by 7.5% SDS-PAGE gel for detection of
ERK1/2, p-ERK1/2, calcineurin, Bcl2, integrin ß1, and
integrin ß3. Proteins were transferred electrophoretically
to nitrocellulose membranes. After blocking in 5% non-fat
dry milk in PBST (phosphate buffered saline with 0.1%
Tween-20, 20 mM Na2HPO4, 115 mM NaCl; pH 7.4), mem-
branes were washed and exposed to the primary antibodies
overnight at 4˚C. Polyclonal anti-ERK1/2 antibody (Sigma)
in 1:750, monoclonal anti-diphosphorylated-ERK1/2 (p-
ERK1/2) antibody (Sigma) in 1:400, polyclonal anti-PP2B
(Pan-calcineurin A) antibody (Cell Signaling Technology,
Danvers, MA) in 1:400, monoclonal anti-Bcl2 antibody
(Upstate, Dundee, Scotland, UK) in 1:500, monoclonal anti-
integrin ß1 antibody (Chemicon-Millipore, Billerica, MA)
in 1:400 and polyclonal anti-integrin ß3 antibody (Cell
Signaling Technology, Danvers, MA) in 1:400 dilution were
used. After washing for 30 min with PBST, membranes
were incubated with secondary antibodies, anti-rabbit IgG
(Bio-Rad Laboratories, CA) in 1:1000 dilution for ERK1/2,
calcineurin and integrin ß3, anti-mouse IgG (Bio-Rad Labo-
ratories) for Bcl2, p-ERK1/2 and integrin ß1 in PBS
containing 1% non-fat dry milk for 1 h at room temperature.
Signals were detected by enhanced chemiluminescence
(Pierce, Rockford, IL) according to the instruction of the
manufacturer.
RT-PCR analysis. For RT-PCR analysis, melanoma cells
were washed three times with RNase-free physiological
NaCl, then the cultures were snap-frozen in liquid nitrogen
and stored at -70˚C. Cell cultures were dissolved in TRIzol
(Applied Biosystems, Foster City, CA), and following
addition of 20% RNase free chloroform (Sigma) samples
were centrifuged at 10,000 x g for 15 min at 4˚C. Samples
were incubated in 500 μl RNase free isopropanol at -20˚C
for 1 h, total RNA was dissolved in RNase free water and
stored at -70˚C. The assay mixture for reverse transcriptase
reactions contained 2 μg RNA, 0.112 μM oligo(dT), 0.5 mM
dNTP and 200 units of High Capacity RT (Applied Bio-
systems) in 1X RT buffer. The sequences of primer pairs for
polymerase chain reaction were as follows: for calcineurin
5'-TAC CCT GCA GTT TGT GAA TT-3' and 5'-ATA TGT
TGA GCA CAT TTA CCA-3', for ERK1/2 5'-CCA GAC
CAT GAT CAC ACA GG-3' and 5'-CTC GTC ACT CGG
GTC GTA AT-3', for Bcl2 5'-GGG TAC GAT AAC CGG
GAG ATA-3' and 5'-GGC CGT ACA GTT CCA AG-3', for
integrin ß1 5'-GCC TAC TTC TGC ACG ATG-3' and 5'-
TAA ATG TCT GTG GCT CCC-3', for integrin ß3 5'-CGT
CCT GAC GCT AAC TGA-3' and 5'-GGT AGT GGA GGC
AGA GTA ATG-3', for GAPDH 5'-CCA GAA GAC TGT
GGA TGG CC-3' and 5'-CTG TAG CCA AAT TCG TTG
TC-3'. At defined annelation degrees 30 cycles were used
and PCR products were analysed by electrophoresis in 1.2%
agarose gel containing ethidium bromide (Amresco Inc.,
Solon, OH) and photographed with a gel documentary
system (DNR Bio-Imaging Systems Ltd., Jerusalem, Israel).
Calcineurin activity assay. For calcineurin activity assays,
cells were harvested and after centrifugation at 10,000 x g
for 10 min at 4˚C, the supernatants were used for enzyme
activity measurements. Activity of calcineurin was assayed
by the release of 32Pi from 32P-labelled protein phosphatase
inhibitor-1 as it was described by Yang et al (27) with some
modifications (28). Radioactivity was determined by Cerenkov
counting in a liquid scintillation counter.
Statistical analysis. Statistical comparisons between control
and test samples were analyzed using Student's paired t-test
for the cell migration, mitochondrial activity and proliferation
assays. 
Results
Both the expression and the activity of calcineurin are higher
in the more malignant HT168 cells. As there are no data
either on the expression or the enzymatic activity of calcineurin
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in melanoma cells, we first aimed to characterise these
parameters in the two cell lines. Cells of both lines expressed
mRNA and protein of calcineurin, but HT168 cells exhibited
a higher level (Fig. 1a and b) as revealed by RT-PCR and
Western blot analyses. Immunocytochemical studies showed
diffuse cytoplasmic distribution of the catalytic subunit of
calcineurin in both cell lines and a delicate nuclear signal was
also visible in the majority of HT168 cells (Fig. 1c and e).
Beside its higher protein level, the enzymatic activity of
calcineurin was also significantly higher in cells of HT168
(Fig. 1g). Since activity of calcineurin is regulated by Ca2+/
calmodulin, we also determined the basal cytosolic free
Ca2+ concentration of melanoma cells. With Fura-2 loading,
approximately 180-200 nM intracellular free Ca2+ was detected
in both cell lines (Fig. 1h).
CsA influenced expression, activity and distribution of
calcineurin. CsA, continuously present in the culture medium,
significantly lowered the activity of calcineurin in both cell
lines, although the inhibition was more pronounced in HT168
cells (Fig. 1g). Parallel to this finding, we observed a probably
compensatory elevation in the expression of calcineurin at
mRNA and protein levels (Fig. 1a and b). CsA did not alter
the diffuse cytoplasmic distribution of calcineurin as
revealed by immunocytochemistry, but the signal was
stronger in the cytoplasm of treated cells than in the control
ones, furthermore, the granular nuclear signal was diminished
by CsA treatment (Fig. 1d and f).
Inhibition of calcineurin alters cell proliferation, viability
and cell death. Cell proliferation and mitochondrial activity
are sensitive parameters to monitor the cytotoxic effects of
any pharmacological interventions. Both proliferation and
mitochondrial activity were higher in HT168 cells than in
WM35 cells under control conditions (Fig. 2a and b). CsA
treatment significantly reduced proliferation in both cell
lines, although HT168 cells responded more prominently
than WM35 (Fig. 2a). Furthermore, repression of mito-
chondrial activity was also observed indicating the reduced
viability of cells. The decrease was significant in HT168
cells and only non-significant effect was detected in WM35
cells (Fig. 2b). CsA caused moderate increase of cell death
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Figure 1. Detection of calcineurin in two different melanoma cell lines. (a) mRNA expression of calcineurin in HT168 and WM35 cells before and after the
application of 2 μM CsA. GAPDH was used as a control. Representative data of five independent experiments. (b) Protein expression level of calcineurin
in untreated control cells and under the effect of 2 μM CsA. Representative measurement of five independent experiments. (c-f) Subcellular localization
of the catalytic subunit of calcineurin by immunochemistry. Untreated cells of HT168 (c), HT168 cells treated with 2 μM CsA (d), untreated WM35
cells (e), WM35 cells treated with 2 μM CsA (f). Original magnification was x40. Representative photomicrographs of four independent experiments.
(g) Enzymatic activity of calcineurin. Asterisks indicate significant (*P<0.05) decrease of calcineurin activity as compared to the respective control.
Representative data of three independent experiments. (h) Free cytosolic Ca2+ level of HT168 and WM35 cells. Basal Ca2+ concentration was determined
at 70% confluency in Fura-2-loaded cells. Experiments were carried out after continuous application of 2 μM CsA measuring 30 cells in each case. Data
represent the mean ± standard error of the mean of three independent experiments.
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as it was detected by FACS analyses using Annexin V or
propidium iodide incorporation methods (Fig. 2c).
Opposite effects of CsA on fibronectin-guided migration of
HT168 and WM35 cells. Investigation of a chemoattractant-
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Figure 2. Effect of CsA on proliferation rate (a) and mitochondrial activity (b) of melanoma cell lines. Proliferation and mitochondrial activity were assessed
by 3H-thymidine incorporation and MTT assay, respectively. Assays were carried out 2 days after continuous treatment by 2 μM CsA. Data represent the
mean ± standard error of the mean of three independent experiments. Asterisks indicate significant decrease (*P<0.05) in 3H-thymidine incorporation or
significant decrease (*P<0.05) in cellular viability as compared to the respective control. (c) Apoptotic and necrotic effect of CsA treatment determined by the
detection of Annexin V DY647 and propidium-iodide with FACS analysis. Quadrant 1 represents cells binding Annexin V DY647 (i.e. early apoptotic cells),
quadrant 4 contains propidium iodide stained cells (i.e. necrotic cells), quadrant 2 shows the combination of the two effects, and quadrant 3 represents living
cells. Representative data of three independent experiments.
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directed migration of tumour cells is an accepted in vitro
model to simulate and estimate the invasiveness and mobility
in tissues. As fibronectin is present both in the basement
membrane of epidermis and in the extracellular matrix of
dermal connective tissue, as well as in the majority of tumour
matrices, it seemed to be a good candidate to use as a chemo-
attractant in Boyden chamber for migration assays of
melanoma cells. Significantly higher number of HT168
cells migrated through the polycarbonate membrane toward
fibronectin under control conditions compared to WM35 cells
(Fig. 3). Application of CsA in the culturing medium of
melanoma cells prior to the migration assay had opposite
effects; migration of HT168 cells was facilitated, while that
of WM35 cells was inhibited as revealed by counting of
migrated cells (Fig. 3). An identical effect was observed
when CsA was present in the culturing medium during the
migration assay (data not shown).
CsA modulates cell shape and actin organization of
melanoma cells. Simultaneous changes of cell shape and
reorganization of actin cytoskeleton are key elements in the
migration of cells. Since inhibition of calcineurin had signi-
ficant effect on fibronectin directed migration of melanoma
cells, we investigated the morphology and the organization
of actin network when CsA was applied. Untreated HT168
and WM35 cells exhibited pronounced morphological
differences. High cellular polymorphism including giant
cells with probably polyploid nuclei were characteristic in
the more malignant HT168, whereas more uniform spindle-
shaped and multipolar cells were visible in the less malignant
cell line (Fig. 4a and c). CsA caused dramatic morphological
changes in both cell lines. The majority of cells in HT168
became more elongated and gained longer processes, WM35
cells lost their long extensions and became more compact
under the effect of CsA. Additionally, cytoplasm of WM35
cells became somehow ‘foamy-like’. Furthermore, compaction
of nuclei and a decreased number of nucleoli were observed
in both cell lines (Fig. 4b and d). Actin network of untreated
HT168 cells formed well defined stress fibers which
became thicker and more developed in the presence of CsA
(Fig. 4e and f). Untreated WM35 cells did not exhibit pro-
nounced actin cables and only a few delicate stress fibers
appeared under the effect of CsA (Fig. 4g and h).
ß1 and ß3 integrin, Bcl-2 and ERK1/2 expressions in
melanoma cell lines. As cells can attach to fibronectin mainly
via ·5ß1 and ·5ß3 integrins, we investigated the expression
of ß1 and ß3 integrin subunits in melanoma cells. We found
that both cell lines express more ß3 than ß1 subunit proteins
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Figure 3. Effect of 2 μM CsA on the migration ability of melanoma cells.
Fibronectin was used as a chemoattractant. Data represent the mean ±
standard error of the mean of five independent experiments and are given in
the average cell number of migrated cells. Asterisks indicate significant
(*P<0.05) decrease or increase in the number of migrated cells as compared
to the respective control.
Figure 4. Melanoma cells visualized with haematoxylin and eosin staining.
HT168 (a), HT168+CsA (b), WM35 (c) and WM35+CsA (d). Original
magnification was x40. TRITC-phalloidin was used to visualize the actin
skeleton system of melanoma cells. HT168 (e), HT168+CsA (f), WM35 (g)
and WM35+CsA (h). Nucleus was visualized with DAPI. Original magni-
fication was x40. Representative photomicrographs of five independent
experiments.
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and the difference was very prominent in the case of WM35
cells (Fig. 5b). Treatment of cells with CsA resulted in
opposite effects in the two different cell lines. WM35 cells
did not show any significant change in the protein level of
either ß1 or ß3 subunits, while cells of HT168 did change
their protein expression pattern: stronger ß1 and weaker ß3
protein signals were detected as compared to the untreated
cells (Fig. 5b). None of the afore-mentioned differences
were detected at the mRNA level (Fig. 5a).
Apoptosis resistance is one of the worst biological pro-
perties of melanoma cells, therefore we investigated the
expression of the anti-apoptotic Bcl-2 and also the expression
and phosphorylation levels of ERK1/2. The latter molecule
is widely accepted as one of the most important factors
responsible for the apoptosis resistance of melanoma cells
(29). Similarly to the results observed for integrins, the
changes of Bcl-2 or ERK1/2 were only detected at protein
levels, mRNA expressions exhibited no significant alterations
(Fig. 5a). Despite this fact, we detected differences either
in the protein level or in the phosphorylation status of
ERK1/2 in control and CsA-treated cells. We did not detect
any significant difference in the expression levels of ERK1/2
of the two cell lines under control conditions. Inhibition
of calcineurin resulted in a significant elevation of unphos-
phorylated ERK1/2 in both cell lines and an extremely
pronounced level of dual-phosphorylated ERK1/2 appeared
in HT168 cells (Fig. 5b). Bcl-2 protein was somewhat less
expressed by WM35 cells than that of HT168 cells under
control conditions, but both cell lines responded to CsA
treatment with a slight increase of Bcl-2 protein level
(Fig. 5b).
Discussion
Our data provide evidence for the presence and the activity
of calcineurin, furthermore, some possible targets of the
enzyme are also suggested in HT168 and WM35 human mela-
noma cell lines. The two cell lines did not exhibit pronounced
differences either in mRNA or protein levels of calcineurin,
but a much higher enzyme activity was detected in HT168
cells. Activity of calcineurin is dependent on changes of
the intracellular Ca-concentration. The basal cytosolic-free
Ca-concentration was found 180-200 nM in both cell lines,
which value is in line with that of reported by Hodgson and
Dong (30) in A2058, the parental cell line of HT168. The
half-maximal activation of calcineurin could require higher
Ca-concentration (400-600 nM), at least in enzyme activity
assay (31). Therefore, we may suppose periodic activation
of different Ca-channels either in the plasma membrane
or in the endoplasmic reticulum of melanoma cells, since
oscillations of intracellular Ca-concentration are also reported
to sensitize cells to Ca-signalling (32). Another possibility is
that Ca-independent regulatory molecules of calcineurin,
such as calcipressin, binding to the regulatory subunit of
calcineurin or cabin1 interacting with activated calcineurin
may be involved in the modulation of its activity in melanoma
cells (33).
CsA is perhaps the best known pharmacological inhibitor
of calcineurin, thus we applied this drug to investigate the
possible effects of calcineurin in melanoma cells. Some
cellular functions were modulated in opposing directions in
the two cell lines. Viability assays detected significant cyto-
toxicity on HT168 cells in the presence of CsA, while WM35
cells did not respond so. This observation may reflect that
more malignant melanoma cells are more sensitive to the
inhibition of calcineurin function. In some aspects the two
cell lines responded to CsA treatment similarly. Activity of
calcineurin was lowered by 30-50%, proliferation of melanoma
cells was attenuated by 50% and the rate of cell death was
moderately affected. Furthermore, CsA caused pronounced
alterations in the morphology of both cell lines, although
the direction of these changes proved to be different. HT168
cells became more elongated, while WM35 cells lost their
processes and became rather polygonal. This observation
is partly in line with those described by Hojo et al (34) who
found that CsA treatment of pulmonary adenocarcinoma
cell line A-549 resulted in morphological changes including
formation of membrane ruffling and numerous pseudopodial
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Figure 5. ß1 and ß3 integrin, Bcl-2 and ERK1/2 expressions in melanoma
cell lines. (a) Effect of 2 μM CsA on the mRNA expression of integrin ß3,
integrin ß1, bcl2 and ERK. GAPDH was used as a control. Representative
measurement of five independent experiments. (b) Protein expression of
integrin ß3, integrin ß1, Bcl2, ERK1/2 and phosphorylation level of ERK1/2
as revealed by Western blot analysis. Representative data of five independent
experiments.
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protrusions. We also observed that nuclei of cells became
more compact and less nucleoli were visible in each
individual nucleus.
The profound effect of CsA treatment on the morphology
of cells of both cell lines raised the possibility of the modu-
lation of mobility/invasiveness of melanoma cells. It is
well known that mobility of different cells including those of
malignant phenotype is promoted by multiple factors such
as adhesion to the extracellular matrix molecules or changes
of intracellular Ca-concentration (18,35). In some cases simul-
taneous involvement of the two events were also reported,
e.g. type IV collagen stimulated intracellular calcium in the
A2058 human melanoma cell line (36), however, fibronectin
failed to induce the same change. On the other hand, results
of Hodgson and Dong (30) elucidated an other aspect of the
relationship of adhesion/migration and intracellular Ca. Type
IV collagen guided migration of A2058 cells was found
effectively abrogated by increased intracellular calcium con-
centration. Nonetheless, both groups (30,36) have suggested
the implication of calcineurin in the altered guided migration
of melanoma cells. Therefore, we investigated the effect
of the inhibition of calcineurin on the fibronectin guided
migration of the two melanoma cell lines. We found that
CsA had pronounced promoting effect on the chemotaxis
of HT168 cells. On the other hand, WM35 cells were signi-
ficantly inhibited in their migration ability by this compound.
Influence of CsA on the migration and the invasiveness
of several tumour types was recently investigated yielding
different results. Sliwa et al (37) reported inhibition of
migration of glioblastoma cells treated by CsA and Yiu and
Toker (38) found that CsA inhibited the migration of breast
cancer cells in an NFAT- and COX-2-dependent manner.
On the contrary, motility and invasiveness of lung adeno-
carcinoma cell line was stimulated by CsA (34). These
contradictory observations might be explained if we suppose
a cell type- and progression-dependent influence of
calcineurin on the migration ability of different tumour cells.
There are several observations describing the role of
calcineurin in the reorganization of actin network of different
cell types, such as neurons (39) or neutrophil granulocytes
(40,41). We also found that beside changes in morphology
of melanoma cells, CsA caused pronounced alterations of
actin network in HT168 cells. The opposite response of the
two cell lines in changes of morphology, actin reorganization
and chemotaxis may imply the possibility of different target
molecules of calcineurin in the two different phases of pro-
gression of melanoma.
Adhesion to the tumour matrix molecules and the chemo-
taxis of malignant cells are influenced by the expression
pattern of receptors to extracellular matrix molecules, such
as integrins (42). Integrin signalling of melanoma cells is
extensively investigated (43) and a wide range of different
integrins is referred to be present in them. According to our
Western blot analysis, both cell lines express more ß3 than
ß1 integrin subunits. It is accepted that melanocytes do not
express ß3 but possess ß1 integrins and during development
of melanoma, the appearance of ß3 integrins is a specific
marker of transition from radial growth phase to vertical
growth phase (44). CsA altered the integrin expression profile
in the two cell lines: HT168 cells switched from ß3 to ß1
integrins, while WM35 cells kept expressing ß3 integrins. To
find the biological implication of this opposite response
requires further investigations, particularly if we consider the
fact that fibronectin guided migration of HT168 cells was
stimulated, while that of WM35 cells was inhibited by CsA.
Nonetheless, it is possible that the difference in the change
of the integrin pattern of melanoma cells in response to CsA
treatment may reflect the involvement of malignancy stage-
dependent role of calcineurin in the regulation of fibronectin
guided migration of melanoma cells.
Beside their high motility, another biological property
providing poor prognosis of melanoma is the high resistance
of the melanoma cells to apoptosis. Sustained overactivation
of MAPKK/ERK pathway is regarded as one of the factors
which protect melanoma cells against apoptosis inducing
chemotherapies. In human keratinocytes, CsA is described to
decrease DNA repair and apoptosis following UV irradiation
(8) and indeed, we found that CsA did not cause significant
cell death either in HT168 or WM35 cells. Parallel to this,
expression and phosphorylation of ERK1/2 was extremely
elevated in CsA treated cells. Moreover, CsA caused increased
expression of anti-apoptotic Bcl2. These data support the
idea that calcineurin might be an important factor in the
regulation of apoptosis in melanoma cells, although inhi-
bition of calcineurin alone did not cause significant alteration
of cell death. Nonetheless, CsA has been described to augment
the apoptotic effect of taxol in urinary bladder cancer cells (45)
and modulation of intracellular calcium level with depleting
intracellular Ca-stores also caused a calcineurin-dependent
apoptosis in prostatic cancer cells (46).
In conclusion, calcineurin plays multiple roles in the
different cellular functions of the two human melanoma
cell lines investigated. Our observations may point out the
involvement of calcineurin in the malignant transformation
of melanocytes in vivo, which is independent from the
alteration of T-lymphocyte function. This idea is supported
by data of Hojo et al (34), drawing our attention to the
possible immunosuppression-independent role of calcineurin
in the development of malignant phenotype of different cell
types.
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